(Reuters) – Adamas Prescribed drugs Inc stated on Tuesday its drug to deal with strolling impairment in sufferers with a number of sclerosis didn’t present the scientific profit the drugmaker hoped for in a late-stage trial, sending shares of the corporate down 45%.

The corporate stated it could assess the potential for the remedy, Gocovri, in MS sufferers earlier than figuring out its continued funding in this system.

Whereas the next dose of the remedy taken at bedtime improved strolling velocity amongst sufferers with a number of sclerosis, it didn’t have any important impact on secondary objectives.

A number of sclerosis is a disabling autoimmune illness that damages…



Source link

Please follow and like us: